|
1
|
Denaro N, Russi EG, Adamo V and Merlano
MC: State-of-the-art and emerging treatment options in the
management of head and neck cancer: News from 2013. Oncology.
86:212–229. 2014.PubMed/NCBI
|
|
2
|
Burris HA III: Dual kinase inhibition in
the treatment of breast cancer: Initial experience with the
EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 9(Suppl 3): 10–15.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kalyankrishna S and Grandis JR: Epidermal
growth factor receptor biology in head and neck cancer. J Clin
Oncol. 24:2666–2672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jedlinski A, Ansell A, Johansson AC and
Roberg K: EGFR status and EGFR ligand expression influence the
treatment response of head and neck cancer cell lines. J Oral
Pathol Med. 42:26–36. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Califano R, Morgillo F, De Mello RA and
Mountzios G: Role of mesenchymal-epithelial transition
amplification in resistance to anti-epidermal growth factor
receptor agents. Ann Transl Med. 3:812015.PubMed/NCBI
|
|
6
|
Privitera G, Luca T, Musso N, Vancheri C,
Crimi N, Barresi V, Condorelli D and Castorina S: In vitro
antiproliferative effect of trastuzumab (Herceptin®) combined with
cetuximab (Erbitux®) in a model of human non-small cell lung cancer
expressing EGFR and HER2. Clin Exp Med. Feb 26–2015.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Erjala K, Sundvall M, Junttila TT, Zhang
N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R and
Elenius K: Signalling via ErbB2 and ErbB3 associates with
resistance and epidermal growth factor receptor (EGFR)
amplification with sensitivity to EGFR inhibitor gefitinib in head
and neck squamous cell carcinoma cells. Clin Cancer Res.
12:4103–4111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoo SB, Kim YJ, Kim H, Jin Y, Sun PL,
Jheon S, Lee JS and Chung JH: Alteration of the
E-cadherin/β-catenin complex predicts poor response to epidermal
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
treatment. Ann Surg Oncol. 20(Suppl 3): S545–S552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mukherjee S, Mazumdar M, Chakraborty S,
Manna A, Saha S, Khan P, Bhattacharjee P, Guha D, Adhikary A,
Mukhjerjee S and Das T: Curcumin inhibits breast cancer stem cell
migration by amplifying the E-cadherin/β-catenin negative feedback
loop. Stem Cell Res Ther. 5:1162014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harrington K, Berrier A, Robinson M, et
al: Randomised Phase II study of oral lapatinib combined with
chemoradiotherapy in patients with advanced squamous cell carcinoma
of the head and neck: Rationale for future randomised trials in
human papilloma virus-negative disease. Eur J Cancer. 49:1609–1618.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Umbreit C, Flanjak J, Weiss C, Erben P,
Aderhold C, Faber A, Stern-Straeter J, Hoermann K and Schultz JD:
Incomplete epithelial-mesenchymal transition in p16-positive
squamous cell carcinoma cells correlates with β-catenin expression.
Anticancer Res. 34:7061–7069. 2014.PubMed/NCBI
|
|
13
|
Krisanaprakornkit S and Iamaroon A:
Epithelial-mesenchymal transition in oral squamous cell carcinoma.
ISRN Oncol. 2012:6814692012.PubMed/NCBI
|
|
14
|
Hay ED: The mesenchymal cell, its role in
the embryo and the remarkable signalling mechanisms that create it.
Dev Dyn. 233:706–720. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumour
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signalling, development and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaimal R, Aljumaily R, Tressel SL, et al:
Selective blockade of matrix metalloprotease-14 with a monoclonal
antibody abrogates invasion, angiogenesis and tumour growth in
ovarian cancer. Cancer Res. 73:2457–2467. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zarrabi K, Dufour A, Li J, Kuscu C,
Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S and Cao J:
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer
cell migration. J Biol Chem. 286:33167–33177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Umbreit C, Aderhold C, Faber A, Sommer JU,
Sauter A, Hofheinz RD, Stern-Sträter J, Hoermann K and Schultz JD:
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and
docetaxel in p16-positive squamous cell carcinoma compared to
HPV-negative HNSCC cells in vitro. Anticancer Res. 33:2457–2465.
2013.PubMed/NCBI
|
|
20
|
Tang YL, Fan YL, Jiang J, Li KD, Zheng M,
Chen W, Ma XR, Geng N, Chen QM, Chen Y and Liang XH: C-kit induces
epithelial-mesenchymal transition and contributes to salivary
adenoid cystic cancer progression. Oncotarget. 5:1491–1501. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al Moustafa AE, Achkhar A and Yasmeen A:
EGF-receptor signalling and epithelial-mesenchymal transition in
human carcinomas. Front Biosci (Schol Ed). 4:671–684. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang JY, Wright JM and Svoboda KK:
Signall transduction pathways involved in epithelial-mesenchymal
transition in oral cancer compared with other cancers. Cells
Tissues Organs. 185:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang ZC, Yi MJ, Ran N, Wang C, Fu P, Feng
XY, Xu L and Qu ZH: Transforming growth factor-β1 induces bronchial
epithelial cells to mesenchymal transition by activating the Snail
pathway and promotes airway remodeling in asthma. Mol Med Rep.
8:1663–1668. 2013.PubMed/NCBI
|
|
24
|
Acevedo VD, Gangula RD, Freeman KW, Li R,
Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M and Spencer DM:
Inducible FGFR-1 activation leads to irreversible prostate
adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer
Cell. 12:559–571. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo F, Parker Kerrigan BC, Yang D, Hu L,
Shmulevich I, Sood AK, Xue F and Zhang W: Post-transcriptional
regulatory network of epithelial-to-mesenchymal and
mesenchymal-to-epithelial transitions. J Hematol Oncol. 7:192014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brabletz T, Hlubek F, Spaderna S,
Schmalhofer O, Hiendlmeyer E, Jung A and Kirchner T: Invasion and
metastasis in colorectal cancer: Epithelial-mesenchymal transition,
mesenchymal-epithelial transition, stem cells and beta-catenin.
Cells Tissues Organs. 179:56–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brabletz T, Jung A, Reu S, Porzner M,
Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T: Variable
beta-catenin expression in colorectal cancers indicates tumour
progression driven by the tumour environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hajra KM and Fearon ER: Cadherin and
catenin alterations in human cancer. Genes Chromosomes Cancer.
34:255–268. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schultz JD, Sommer JU, Hoedt S, Erben P,
Hofheinz RD, Faber A, Thorn C, Hörmann K and Sauter A:
Chemotherapeutic alteration of β-catenin and c-kit expression by
imatinib in p16-positive squamous cell carcinoma compared to
HPV-negative HNSCC cells in vitro. Oncol Rep. 27:270–280.
2012.PubMed/NCBI
|
|
30
|
Brabletz T: The Rudolf Virchow Prize 2001.
The role of the oncoprotein beta-catenin in the progression of
colorectal cancers. Verh Dtsch Ges Pathol. 85:243–249. 2001.(In
German). PubMed/NCBI
|
|
31
|
Zhang X and Hao J: Development of
anticancer agents targeting the Wnt/β-catenin signaling. Am J
Cancer Res. 5:2344–2360. 2015.(Review). PubMed/NCBI
|
|
32
|
Maseki S, Ijichi K, Tanaka H, Fujii M,
Hasegawa Y, Ogawa T, Murakami S, Kondo E and Nakanishi H:
Acquisition of EMT phenotype in the gefitinib-resistant cells of a
head and neck squamous cell carcinoma cell line through
Akt/GSK-3β/snail signallling pathway. Br J Cancer. 106:1196–1204.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
35
|
Shah AN, Summy JM, Zhang J, Park SI,
Parikh NU and Gallick GE: Development and characterization of
gemcitabine-resistant pancreatic tumour cells. Ann Surg Oncol.
14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vig N, Mackenzie IC and Biddle A:
Phenotypic plasticity and epithelial-to-mesenchymal transition in
the behaviour and therapeutic response of oral squamous cell
carcinoma. J Oral Pathol Med. 44:649–655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Klussmann JP, Preuss SF and Speel EJ:
Human papillomavirus and cancer of the oropharynx. Molecular
interaction and clinical implications. HNO. 57:113–122. 2009.(In
German). View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Scanlon CS, Van Tubergen EA, Inglehart RC
and D'Silva NJ: Biomarkers of epithelial-mesenchymal transition in
squamous cell carcinoma. J Dent Res. 92:114–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koontongkaew S: The tumour
microenvironment contribution to development, growth, invasion and
metastasis of head and neck squamous cell carcinomas. J Cancer.
4:66–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seiki M: Membrane-type 1 matrix
metalloproteinase: A key enzyme for tumour invasion. Cancer Lett.
194:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schultz JD, Muhlheim K, Erben P, et al:
Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression
by imatinib in HPV-transformed squamous cell carcinoma compared to
HPV-negative HNSCC in vitro. Oncology Reports. 26:1099–1109.
2011.PubMed/NCBI
|
|
43
|
Cervantes-Arias A, Pang LY and Argyle DJ:
Epithelial-mesenchymal transition as a fundamental mechanism
underlying the cancer phenotype. Vet Comp Oncol. 11:169–184. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rodrigues IS, Lavorato-Rocha AM, de Maia
MB, Stiepcich MM, de Carvalho FM, Baiocchi G, Soares FA and Rocha
RM: Epithelial-mesenchymal transition-like events in vulvar cancer
and its relation with HPV. Br J Cancer. 109:184–194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Richter P, Umbreit C, Franz M and Berndt
A, Grimm S, Uecker A, Böhmer FD, Kosmehl H and Berndt A: EGF/TGFβ1
co-stimulation of oral squamous cell carcinoma cells causes an
epithelial-mesenchymal transition cell phenotype expressing laminin
332. J Oral Pathol Med. 40:46–54. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lee CG, McCarthy S, Gruidl M, Timme C and
Yeatman TJ: MicroRNA-147 induces a mesenchymal-to-epithelial
transition (MET) and reverses EGFR inhibitor resistance. PLoS One.
9:e845972014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Valenta T, Hausmann G and Basler K: The
many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sahu N and Grandis JR: New advances in
molecular approaches to head and neck squamous cell carcinoma.
Anticancer Drugs. 22:656–664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Smilek P, Neuwirthova J, Jarkovsky J,
Dusek L, Rottenberg J, Kostrica R, Srovnal J, Hajduch M, Drabek J
and Klozar J: Epidermal growth factor receptor (EGFR) expression
and mutations in the EGFR signalling pathway in correlation with
anti-EGFR therapy in head and neck squamous cell carcinomas.
Neoplasma. 59:508–515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ciardiello F and Tortora G: Epidermal
growth factor receptor (EGFR) as a target in cancer therapy:
Understanding the role of receptor expression and other molecular
determinants that could influence the response to anti-EGFR drugs.
Eur J Cancer. 39:1348–1354. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fumagalli I, Dugue D, Bibault JE,
Clémenson C, Vozenin MC, Mondini M and Deutsch E: Cytotoxic effect
of lapatinib is restricted to human papillomavirus-positive head
and neck squamous cell carcinoma cell lines. Onco Targets Ther.
8:335–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lamouille S, Subramanyam D, Blelloch R and
Derynck R: Regulation of epithelial-mesenchymal and
mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell
Biol. 25:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
